Pharmacokinetic Drug Interaction Studies with Enzalutamide

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate before chemotherapy. N Engl J Med. 2014;371(5):424–33.

Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, et al. Clinical pharmacokinetics of enzalutamide. Clin Pharmacokinet. 2015 [Epub ahead of print].

U.S. Department of Health and Human Services. Guidance for industry: bioanalytical method validation, 2001. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107 . Accessed 13 Feb 2015.

Bennett D, Gibbons JA, Mol R, Ohtsu Y, Williard C. Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC–MS/MS. Bioanalysis. 2014;6(6):737–44.

Gemfibrozil tablets [prescribing information], 2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=636 . Accessed 13 Feb 2015.

Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37(4):778–84.

Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5 + 1 cocktail”. Clin Pharmacol Ther. 2003;74(5):437–47.

Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652–9.

Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. 2006;61(1):70–8.

Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther. 2009;31(2):286–98.

Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006;50(4):1130–5.

Padhi D, Salfi M, Emery M. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents: a randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D. 2008;9(5):335–43.

Shord SS, Chan LN, Camp JR, Vasquez EM, Jeong HY, Molokie RE, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol. 2010;69(2):160–6.

Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928–35.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42(1):52–60.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Semi-mechanistic population pharmacokinetic drug–drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet. 2010;49(1):53–66.

American Cancer Society. Cancer facts and figures 2014. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index . Accessed 13 Feb 2015.

Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.

Haider SI, Johnell K, Thorsland M, Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Ther. 2007;45(12):643–53.

Husson N, Watfa G, Laurain MC, Perret-Guillaume C, Niemier JY, Miget P, et al. Characteristics of polymedicated (≥4) elderly: a survey in a community-dwelling population aged 60 years and over. J Nutr Health Aging. 2014;18(1):87–91.

U.S. Department of Health and Human Services. Guidance for industry. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf . Accessed 13 Feb 2015.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of enzalutamide in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;24;375(9724):1437–46.

Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62:1238–49.

Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev. 2010;42(1):55–61.

Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos. 2010;38(11):2007–13.

Astellas Pharma Inc. (Astellas Pharma Europe B.V.) Drug–drug interaction study with MDV3100 (ASP9785) and gemfibrozil and itraconazole. [ClinicalTrials.gov identifier NCT01913379]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov . Accessed 23 Apr 2015.

Astellas Pharma Inc. (Astellas Pharma Europe B.V.) Drug–drug interaction study with MDV3100 and a cocktail of substrates. [ClinicalTrials.gov identifier NCT01911728]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov . Accessed 23 Apr 2015.

Data on file, Medivation, 2012.